Can-Fite BioPharma (CANF) Institutional Ownership $0.68 +0.03 (+4.04%) As of 01:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Can-Fite BioPharma (NYSE:CANF)CurrentInstitutional OwnershipPercentage21.00%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$441.80KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$16.53K Get CANF Insider Trade Alerts Want to know when executives and insiders are buying or selling Can-Fite BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CANF Institutional Buying and Selling by Quarter Can-Fite BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/29/2025Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 4/8/2025Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 2/17/2025BNP Paribas Financial Markets25,185$41K0.0%N/A0.711% 2/14/2025Two Sigma Securities LLC19,395$32K0.0%-34.4%0.548% 1/30/2025Rhumbline Advisers26,880$44K0.0%+58.6%0.759% 8/15/2024Armistice Capital LLC518,853$1.34M0.0%+35.5%14.657% 2/13/2024Armistice Capital LLC154,363$340K0.0%N/A4.361% 1/17/2024Schechter Investment Advisors LLC20,077$44K0.0%N/A0.567% 2/10/2022Acadian Asset Management LLC28,601$36K0.0%-75.1%0.105% 11/16/2021Cetera Advisor Networks LLC130,776$217K0.0%-16.9%0.607% 10/15/2021 Fifth Third Bancorp30,000$50K0.0%N/A0.149% 8/6/2021StoneX Group Inc.40,000$91K0.0%N/A0.233% 5/21/2021Citadel Advisors LLC60,077$148K0.0%N/A0.349% 5/19/2021Virtu Financial LLC46,294$114K0.0%-37.5%0.269% 5/18/2021Citadel Advisors LLC60,077$148K0.0%N/A0.349% 5/18/2021Jane Street Group LLC10,665$26K0.0%N/A0.062% (Data available from 1/1/2016 forward) CANF Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CANF shares? During the previous two years, the following institutional investors and hedge funds held shares of Can-Fite BioPharma shares: Armistice Capital LLC ($1.34M), Rhumbline Advisers ($57K), Schechter Investment Advisors LLC ($44K), and BNP Paribas Financial Markets ($41K), Two Sigma Securities LLC ($32K).Learn more on Can-Fite BioPharma's institutional investors. What percentage of Can-Fite BioPharma's stock is owned by institutional investors? 21.00% of Can-Fite BioPharma's stock is owned by institutional investors. Learn more on CANF's institutional investor holdings. Which institutional investors have been buying Can-Fite BioPharma's stock? The following institutional investors have purchased Can-Fite BioPharma's stock in the last 24 months: Armistice Capital LLC ($290.42K), Rhumbline Advisers ($32.71K), BNP Paribas Financial Markets ($25.19K), and Schechter Investment Advisors LLC ($20.08K). How much institutional buying is happening at Can-Fite BioPharma? Institutional investors have bought a total of 193,951 shares in the last 24 months. This purchase volume represents approximately $441.80K in transactions. Which of Can-Fite BioPharma's major shareholders have been selling company stock? The following institutional investors have sold Can-Fite BioPharma stock in the last 24 months: Two Sigma Securities LLC ($10.18K). How much institutional selling is happening at Can-Fite BioPharma? Institutional investors have sold a total of 10,175 shares in the last 24 months. This volume of shares sold represents approximately $16.53K in transactions. Related Companies Ernexa Therapeutics Major Shareholders Promis Neurosciences Major Shareholders Leap Therapeutics Major Shareholders Bullfrog AI Major Shareholders Synaptogenix Major Shareholders Neuphoria Therapeutics Major Shareholders Flora Growth Major Shareholders Minerva Neurosciences Major Shareholders HOOKIPA Pharma Major Shareholders IM Cannabis Major Shareholders This page (NYSE:CANF) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
